# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
On Thursday, Cathie Wood-led Ark Invest made notable adjustments to its portfolio, including a significant sell-off of Robinhoo...
Cathie Wood's flagship ARK Innovation ETF has been navigating through significant losses, showcasing the challenges faced b...
Citigroup analyst David Lebowitz maintains Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and lowers the price target fr...
BMO Capital analyst Kostas Biliouris maintains Intellia Therapeutics (NASDAQ:NTLA) with a Outperform and raises the price ta...
Wedbush analyst David Nierengarten reiterates Intellia Therapeutics (NASDAQ:NTLA) with a Neutral and maintains $29 price tar...
-SEC Filing